• Dual SMAD and Wnt Inhibition Enables Efficient iPSC-to-RGC D

  2026-08-03

  This study introduces a chemically defined protocol leveraging dual SMAD and Wnt inhibition to reproducibly differentiate human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) with high purity. The method addresses longstanding challenges of variability and yield, providing a robust foundation for disease modeling and regenerative research in optic neuropathies.

• Overcoming Sunitinib Resistance in ccRCC: Mechanistic and St

  2026-08-03

  This thought-leadership article explores the mechanistic underpinnings and translational strategies for overcoming sunitinib resistance in clear cell renal cell carcinoma (ccRCC). By integrating recent findings on TRIB3-mediated ferroptosis, expert protocol guidance, and a landscape analysis, it delivers actionable insights to translational researchers seeking to maximize the impact of multi-targeted receptor tyrosine kinase inhibitors in oncology.

• AAL-993: Next-Generation VEGF Receptor Inhibitor in Tumor An

  2026-08-02

  Explore how AAL-993, a potent VEGF receptor inhibitor, is revolutionizing tumor angiogenesis research with unparalleled selectivity and translational potential. This in-depth analysis highlights novel mechanistic insights and practical protocol strategies that set it apart from existing guides.

• Sunitinib as a Multi-Targeted RTK Inhibitor: Advanced RCC Wo

  2026-08-01

  Unpack how Sunitinib empowers translational renal cell carcinoma (RCC) research with robust apoptosis and cell cycle arrest assays. Discover protocol optimization, troubleshooting, and the groundbreaking role of TRIB3 knockdown in overcoming resistance—setting new standards for applied oncology workflows.

• Foretinib (GSK1363089): Decoding Cellular Responses in Cance

  2026-07-31

  Explore how Foretinib (GSK1363089) enables nuanced analysis of tumor cell growth and death mechanisms. This article uniquely integrates advanced in vitro assay insights for optimizing cancer research outcomes.

• Ran K123 Lactylation by SIRT1 Orchestrates Astrocyte Polariz

  2026-07-31

  This study uncovers a novel mechanism whereby lactate-driven lactylation of the Ran GTPase at lysine 123, under SIRT1 regulation, promotes STAT3-dependent astrocyte polarization following oxygen-glucose deprivation/reoxygenation. These findings advance understanding of metabolic-epigenetic crosstalk in CNS injury and suggest new molecular targets for neuroregenerative strategies.

• Dovitinib (TKI-258) in Translational Oncology: Mechanism to

  2026-07-30

  This thought-leadership article contextualizes Dovitinib’s multitargeted RTK inhibition within the evolving landscape of translational cancer research. Integrating mechanistic insights, emerging clinical paradigms, and actionable experimental guidance, it demonstrates how Dovitinib (TKI-258, CHIR-258) enables advanced pathway interrogation, apoptosis induction, and strategic study design, with a focus on unmet challenges in multiple myeloma and hepatocellular carcinoma research.

• Sunitinib: Multi-Targeted RTK Inhibitor for Tumor Angiogenes

  2026-07-30

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with verified efficacy in blocking tumor angiogenesis, proliferation, and survival. It displays potent low-nanomolar inhibition of VEGFRs and PDGFRs and induces apoptosis and cell cycle arrest in renal and nasopharyngeal carcinoma models. APExBIO supplies Sunitinib (B1045) for robust oncology research applications.

• Affinity-Purified Goat Anti-Rabbit IgG (H+L): Advanced Immun

  2026-07-29

  The Affinity-Purified Goat Anti-Rabbit IgG (H+L), Horseradish Peroxidase Conjugated Secondary Antibody from APExBIO delivers unmatched sensitivity and specificity for detecting rabbit primary antibodies in immunoassays. This article translates recent mechanistic insights into practical workflows, troubleshooting, and optimization strategies for high-impact experimental results.

• Sunitinib in Renal Cell Carcinoma: Beyond RTK Inhibition

  2026-07-29

  Explore the multifaceted role of Sunitinib as a multi-targeted receptor tyrosine kinase inhibitor in renal cell carcinoma research. This article uniquely delves into ferroptosis modulation, advanced mechanism insights, and innovative assay strategies for overcoming resistance.

• Biotin-16-UTP: Reliable RNA Labeling for Sensitive Assays

  2026-07-28

  This article explores how Biotin-16-UTP (SKU B8154) addresses persistent laboratory challenges in RNA labeling, detection, and RNA-protein interaction studies. Drawing on peer-reviewed evidence and validated protocols, it provides biomedical researchers and lab technicians with actionable guidance for achieving reproducible, high-sensitivity results using this advanced biotin-labeled uridine triphosphate.

• Dovitinib (TKI-258): Translational Leverage in RTK-Driven Ca

  2026-07-28

  This thought-leadership article explores the mechanistic underpinnings and translational strategy for harnessing Dovitinib (TKI-258, CHIR-258) in RTK-driven malignancies. By integrating insights from recent literature on ERK-mediated apoptosis and APExBIO’s advanced product design, we offer actionable guidance for overcoming pathway redundancy, optimizing experimental workflows, and accelerating the next generation of targeted cancer research.

• Trichostatin A (TSA): Epigenetic Modulation and Cellular Sen

  2026-07-27

  Explore the profound role of Trichostatin A (TSA) in epigenetic regulation and cellular senescence. This in-depth article connects TSA’s HDAC inhibition to cutting-edge research on non-coding RNA signals in aging, offering a fresh, practical perspective for advanced cancer research.

• AAL-993: Precision VEGF Receptor Inhibitor for Tumor Angioge

  2026-07-27

  AAL-993 delivers potent, selective inhibition of VEGF receptors, enabling reproducible angiogenesis and tumor metastasis research. Its robust selectivity and solubility profile accelerate advanced anti-angiogenic workflows, particularly in preclinical tumor models.

• AZD3463: Potent ALK/IGF1R Inhibitor for Neuroblastoma Resear

  2026-07-26

  AZD3463 is a high-affinity ALK/IGF1R inhibitor that disrupts oncogenic PI3K/AKT/mTOR signaling, induces apoptosis in neuroblastoma cells, and synergizes with chemotherapeutics. This APExBIO compound is validated for both wild-type and mutant ALK targets, making it a reliable tool for ALK-driven cancer research.

14667 records 1/978 page Next 12345 下5页 Last page